Rein Therapeutics (RNTX) Fundamental Analysis: Revenue, Earnings & Valuation

8.35 / 10

Outperform

Fundamentally, RNTX scores outperformance with strong interest coverage (35.1), robust PB‑ROE (-0.60), high inventory turnover (103.9) and rapid revenue growth (operating YoY 177%). However, current liabilities represent 85% of total liabilities and long‑term debt to working capital is modest, warranting caution.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight28.83%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.40%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.29%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value85.36

Score1/3

Weight-4.60%

1M Return-1.69%

PB-ROE

Value-0.60

Score3/3

Weight36.32%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value6.39

Score1/3

Weight-1.94%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.34%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.16%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.16%

1M Return-1.13%

Asset-MV

Value-0.49

Score3/3

Weight50.62%

1M Return11.61%

Is RNTX undervalued or overvalued?

RNTX scores 8.35/10 on fundamentals and holds a Discounted valuation at present. Backed by its -139.87% ROE, 0.00% net margin, -0.68 P/E ratio, 2.01 P/B ratio, and 44.16% earnings growth, these metrics solidify its Outperform investment rating.